1 / 9

Background Issues

Maternal SSRI-Use During Pregnancy and Neonatal Neurobehavioral Outcome Philip Sanford Zeskind, Ph.D. Director, Neurodevelopmental Research Department of Pediatrics Carolinas Medical Center - Charlotte and University of North Carolina – Chapel Hill. Background Issues.

madison
Télécharger la présentation

Background Issues

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Maternal SSRI-Use During Pregnancy and Neonatal Neurobehavioral OutcomePhilip Sanford Zeskind, Ph.D.Director, Neurodevelopmental ResearchDepartment of PediatricsCarolinas Medical Center - CharlotteandUniversity of North Carolina – Chapel Hill

  2. Background Issues • High rates of maternal depression and SSRI-use among women of child-bearing age • Serotonin levels, affected by maternal SSRI-use, has fundamental role in cell development and brain function • Determining whether this neurotransmitter has adverse effects on development has been based on studies mostly using measures of birthweight, preterm birth and physical anomalies

  3. Methodological Issues • All infants full birthweight, in term nursery a. no abnormal signs on routine physical and neurological examinations • 17 SSRI-exposed and 17 non-exposed • matched on maternal age, cigarette-use and SES • no differences in demographic characteristics • Studied via direct, blinded observation and measurement a. not based on medical record review

  4. Neurobehavioral OutcomesSSRI-exposed infants: • Greater tremulousness • Increased startles (arousals) • Greater generalized motor activity • Disrupted Sleep-State Architecture a. Increased REM Sleep b. More rigid state organization c. Depressed range of states • Disrupted autonomic organization (HRV) All measures previously used to detect effects of prenatal drug exposure and/or to differentiate high risk infants

  5. Neurodevelopmental EffectsSSRI-exposed Infants: • Lower gestational age by 1 week • Within a full birthweight sample in term nursery • Similar to previous findings • A symptom of other developmental problems affecting maturation rate and maternal-fetus interactions • Often interpreted as the problem or complication • Associated with development of autonomic regulation (HRV and startles)

  6. Effects on Further Development • Developmental and drug-toxicology literatures have clearly shown these neurobehaviors to be related to subsequent development • Emphasis on measures of autonomic and behavioral regulation • Less emphasis on standardized tests (e.g., IQ, language) • Unsolicited letters and email describing observable motor effects still evident at 2 years • Supports the one long-term effect documented on motor development from 6-24 month year-olds

  7. Withdrawal Syndrome? • Withdrawal Syndrome • Neurobehaviors may reflect effects of sudden withdrawal from medication • Some suggest providing additional SSRIs in neonatal period to help adaptation • Serotonin Syndrome • Fetus bathed in serotonin during development of nervous system • Direct neurotoxic effects • Effects on synaptic development, adaptation and function • Provision of additional SSRIs to ease withdrawal may be contraindicated

  8. Conclusions • Maternal use of SSRIs during pregnancy may disrupt neurobehavioral development of newborn infant. • Birthweight, preterm birth and physical anomalies are insufficient measures of effects of prenatal SSRI-exposure. • Neurobehavioral effects may be evidence of direct neurotoxic effects on development of nervous system, as well as a withdrawal syndrome. • Effects of exposure during nervous system development different than withdrawal after nervous system developed in adults.

  9. A Question of Balance A careful cost-benefit analysis should be discussed by physician and patient when considering to use SSRIs during pregnancy to treat maternal depression.

More Related